Seeking Alpha

Ohad Hammer

 
View as an RSS Feed
View Ohad Hammer's Articles BY TICKER:
  • Incyte's Jakafi Is Likely A $1 Billion Drug
    Feb. 27, 2013 INCY 1 Comment
  • Onyx - A 'Must Own' Biotech For 2013
    Jan. 28, 2013 ONXX 3 Comments
  • Biotech Portfolio Update: 2012 Summary And 2013 Outlook
    Dec. 24, 2012 ARQL, ARRY, AVEO 11 Comments
  • ASH 2012 Preview: Top Picks For Upcoming Blood Cancer Meeting
    Nov. 12, 2012 INCY, ARRY, SGEN 2 Comments
  • AVEO Pharmaceuticals: Attractive Following Recent De-Risking Events
    Oct. 22, 2012 AVEO 7 Comments
  • Winners Of ESMO 2012
    Oct. 8, 2012 ARIA, EXEL, SNTA 6 Comments
  • Exelixis: First Partnered Program Enters Phase III
    Oct. 3, 2012 EXEL 8 Comments
  • Seattle Genetics: Positive Read-Through From Roche's Investor Day
    Sep. 10, 2012 SGEN 9 Comments
  • Upcoming Catalysts For Exelixis And Immunogen
    Aug. 27, 2012 EXEL, IMGN 9 Comments
  • Synta - The Signal Looks Real
    Jul. 10, 2012 SNTA 5 Comments
  • Winners Of ASCO 2012
    Jun. 11, 2012 EXEL, SGEN, ARQL 12 Comments
  • Drugs To Watch At ASCO 2012
    May. 29, 2012 EXEL, IMGN, AZN 15 Comments
  • Gilead's Hematology Pipeline: Transformative And Under-Appreciated
    May. 6, 2012 GILD 3 Comments
  • Threshold Scores Big With Pancreatic Cancer Data
    Mar. 5, 2012 THLD 9 Comments
  • Biotech Stocks To Watch In 2012
    Feb. 6, 2012 ARRY, CLDX, EXEL 9 Comments
  • Arqule's Strategy Continues To Generate Value
    Jan. 23, 2012 ARQL 2 Comments
  • AVEO: More Open Questions Than Answers
    Jan. 8, 2012 AVEO 12 Comments
  • 5 Winners Of American Society Of Hematology 2011
    Dec. 19, 2011 PCYC, MITI, RHHBF 6 Comments
  • Pfizer's Xalkori: The Story Can Only Get Better
    Nov. 28, 2011 PFE 1 Comment
  • Exelixis: Setting The Facts Straight
    Editors' Pick • Nov. 7, 2011 EXEL 14 Comments
  • Micromet Unveils Another Fast Route To Market, Marks Pfizer As Lead Competitor
    Oct. 16, 2011 MITI 14 Comments
  • Bristol-Myers Squibb Zeroes In On A Blockbuster Cancer Drug
    Sep. 27, 2011 BMY 14 Comments
  • Exelixis: Still Promising, Still Controversial
    Aug. 22, 2011 EXEL 6 Comments
  • Celldex's Vaccine Gets a Boost
    Aug. 8, 2011 CLDX Comment!
  • Why It's Time to Sell ImmunoGen
    Jul. 25, 2011 IMGN 11 Comments
  • 5 Oncology Drugs Available for Partnering (Part II)
    Jul. 5, 2011 MITI, PCYC, SNTA 3 Comments
  • Drugs to Watch at ASCO 2011
    Jun. 2, 2011 BMY, LLY, ARQL 10 Comments
  • 5 Oncology Drugs Available for Partnering
    Apr. 27, 2011 EXEL, ECYT, CLDX 5 Comments
  • Putting a Price Tag on Synta's Lead Drug Activities
    Mar. 20, 2011 SNTA Comment!
  • Morphosys' Growth Story Remains Intact
    Mar. 7, 2011 MPHSF, NVS, IMGN 8 Comments
  • Exelixis: Going Where No Drug Has Gone Before
    Feb. 23, 2011 EXEL 2 Comments
  • As Seattle Genetics Strengthens Its Foothold Within Genentech, What About Immunogen?
    Feb. 14, 2011 SGEN, IMGN 4 Comments